Brian Babin calls for audits on COVID loan distribution

Brian Babin calls for audits on COVID loan distribution
Brian Babin U.S. House of Representatives from Texas's 36th district — Official U.S. House Headshot
0Comments

Brian Babin, a member of the U.S. Congress representing Texas’ 36th district since 2015, shared several statements on social media addressing issues ranging from financial audits to immigration policies and community outreach.

On March 10, 2025, Babin expressed concerns about potential misuse of COVID-19 loans. He stated, “Kids in kindergarten got MILLIONS in COVID loans. People older than anyone alive got MILLIONS in SBA loans, and Biden’s bureaucrats looked the other way. The corruption runs DEEP. It’s time to audit EVERYTHING! #FollowTheMoney”.

Later that day, Babin commented on immigration policy related to individuals supporting terrorist organizations. He tweeted at 18:24 UTC, “No more free passes for Hamas sympathizers. Stand with terrorists? Then say goodbye to your visa and hello to a one-way ticket to Gaza.”

In another post on March 10 at 19:11 UTC, Babin announced upcoming mobile office events aimed at assisting constituents in Harris and Chambers counties. He wrote, “TX-36: Don’t forget, this week my staff is hitting the road! We’re hosting mobile offices in Harris and Chambers counties to assist you. Mark your calendars and stop by, we’re here to help!”



Related

Grace Graham, Deputy Commissioner for Policy, Legislation, and International Affairs of FDA

Cities located in Chambers County saw an FDA inspection of 1 company in Q1

There was one company in a city associated with Chambers County that received an FDA inspection in the first quarter of 2026, according to the U.S. Food and Drug Administration.

Caleb Michaud, Acting Associate Commissioner for External Affairs of FDA

FDA conducts Feb. 12 inspection at AMPAC Fine Chemicals Texas, LLC in La Porte

FDA records show an inspection focused on drug quality assurance took place at AMPAC Fine Chemicals Texas, LLC in La Porte on Feb. 12.

Sara Brenner, Principal Deputy Commissioner at FDA

FDA inspects Octapharma Plasma in Pasadena on Feb. 26, finds no required action

The Food and Drug Administration inspected Octapharma Plasma, Inc. in Pasadena on Feb. 26, reviewing blood and blood products, as reflected in data from the agency’s website.